We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+10.01%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$111M
AUM Growth
+$2.3M
Cap. Flow
+$4.8M
Cap. Flow %
4.31%
Top 10 Hldgs %
45.14%
Holding
70
New
3
Increased
23
Reduced
5
Closed
7
Avg Time Held Equity + Options
5.5 quarters
Top 10 Avg Time Held Equity + Options
2.9 quarters
Top 20 Avg Time Held Equity + Options
4.2 quarters
Avg Time Held Equity only
5.7 quarters
Top 10 Avg Time Held Equity only
3.1 quarters
Top 20 Avg Time Held Equity only
4.9 quarters

Top Buys

Rank Stock Value
1
BIVV
Bioverativ Inc. Common Stock
BIVV
+$648K
2
UTHR icon
United Therapeutics
UTHR
+$525K
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$509K
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$340K
5
SGEN
Seagen Inc. Common Stock
SGEN
+$316K

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$613K
2
MYGN icon
Myriad Genetics
MYGN
+$527K
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$404K
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$220K
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$140K

Sector Composition

Rank Sector Weight
1 Healthcare 73.61%
2 Miscellaneous 26.05%
3 Real Estate 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
QGEN icon
26
Qiagen
QGEN
$9.38B
$2.03M 1.82%
60,753
+7,191
+13% +$248K
2017 Q1
2 quarters
BMRN icon
27
BioMarin Pharmaceuticals
BMRN
$10.5B
$1.85M 1.66%
19,926
+3,164
+19% +$280K
2014 Q4
11 quarters
ALXN
28
DELISTED
Alexion Pharmaceuticals
ALXN
$1.61M 1.44%
11,447
+1,921
+20% +$261K
2014 Q4
11 quarters
LABU icon
29
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$553M
$1.37M 1.23%
800
– –
2016 Q1
6 quarters
LLY icon
30
CALL
Eli Lilly
LLY
$1.04T
$1.28M 1.15%
15,000
– –
2016 Q4
3 quarters
LOXO
31
DELISTED
Loxo Oncology, Inc
LOXO
$1.27M 1.14%
13,800
– –
2017 Q2
1 quarter
CLVS
32
DELISTED
Clovis Oncology, Inc.
CLVS
$1.24M 1.11%
15,000
– –
2016 Q4
3 quarters
KPTI icon
33
Karyopharm Therapeutics
KPTI
$9.69M
$1.1M 0.99%
6,667
– –
2017 Q2
1 quarter
PRTK
34
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1M 0.9%
40,000
– –
2015 Q4
7 quarters
PCRX icon
35
Pacira BioSciences
PCRX
$1.45B
$939K 0.84%
25,000
– –
2016 Q3
4 quarters
GILD icon
36
CALL
Gilead Sciences
GILD
$183B
$810K 0.73%
10,000
– –
2017 Q1
2 quarters
AXSM icon
37
Axsome Therapeutics
AXSM
$8.19B
$741K 0.66%
133,500
– –
2017 Q1
2 quarters
JUNO
38
DELISTED
Juno Therapeutics, Inc.
JUNO
$660K 0.59%
14,720
-3,250
-18% -$111K
2016 Q3
4 quarters
TSRO
39
DELISTED
TESARO, Inc.
TSRO
$646K 0.58%
5,000
– –
2016 Q4
3 quarters
ADMS
40
DELISTED
Adamas Pharmaceuticals
ADMS
$635K 0.57%
30,000
– –
2015 Q4
7 quarters
RARE icon
41
Ultragenyx Pharmaceutical
RARE
$1.47B
$634K 0.57%
11,899
+5,742
+93% +$340K
2016 Q1
6 quarters
BIVV
42
DELISTED
Bioverativ Inc. Common Stock
BIVV
$631K 0.57%
+11,056
New +$648K
2017 Q3
0 quarters
NBIX icon
43
Neurocrine Biosciences
NBIX
$13.7B
$591K 0.53%
9,644
+4,469
+86% +$236K
2016 Q3
4 quarters
ACAD icon
44
Acadia Pharmaceuticals
ACAD
$3.21B
$589K 0.53%
+15,639
New +$509K
2017 Q3
0 quarters
GRFS icon
45
Grifois
GRFS
$4.88B
$543K 0.49%
24,805
+11,920
+93% +$247K
2016 Q2
5 quarters
CRL icon
46
Charles River Laboratories
CRL
$14.3B
$535K 0.48%
4,955
+2,393
+93% +$246K
2016 Q4
3 quarters
GILD icon
47
Gilead Sciences
GILD
$183B
$524K 0.47%
6,462
+3,206
+98% +$245K
2016 Q4
3 quarters
MDCO
48
DELISTED
Medicines Co
MDCO
$519K 0.47%
14,000
– –
2015 Q4
7 quarters
TECH icon
49
Bio-Techne
TECH
$11.4B
$516K 0.46%
17,072
+8,624
+102% +$256K
2016 Q4
3 quarters
IQV icon
50
IQVIA
IQV
$42.9B
$515K 0.46%
5,413
+2,492
+85% +$231K
2016 Q2
5 quarters
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q3 2017 Portfolio in Review

As of Q3 2017, Opus Point Partners Management held 70 positions worth $111M, up 2.1% from $109M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Opus Point Partners Management deployed $4.8M of net new capital in Q3 2017, opening 3 new positions and adding to 23 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 11,056 shares worth $631K.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $140K trimmed.

  • Opus Point Partners Management's largest Q3 2017 buy was Bioverativ Inc. Common Stock: 11,056 shares worth $631K.
  • Opus Point Partners Management added most to Ultragenyx Pharmaceutical in Q3 2017, an estimated $340K increase.
  • Opus Point Partners Management's biggest Q3 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $140K.
  • Opus Point Partners Management fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $613K.
  • Opus Point Partners Management's ten largest holdings make up 45% of its $111M portfolio in Q3 2017.
  • Opus Point Partners Management opened 3 new positions and closed 7 in Q3 2017.
  • Opus Point Partners Management's portfolio value rose 2.1% quarter-over-quarter to $111M.

Based on Opus Point Partners Management's 13F filing for Q3 2017, filed 14 Nov 2017.